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signals are absent. Antal et al. reinterpret
a protein kinase C bII crystal structure to
show that its Ca2+-sensing C2 domain
autoinhibits by binding over the kinase
domain, unveiling an interface that can
potentially be therapeutically targeted to
enhance or restrain activity.
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The signaling output of protein kinase C (PKC) is
exquisitely controlled, with its disruption resulting
in pathophysiologies. Identifying the structural basis
for autoinhibition is central to developing effective
therapies for cancer, where PKC activity needs to
be enhanced, or neurodegenerative diseases, where
PKC activity should be inhibited. Here, we reinterpret
a previously reported crystal structure of PKCbII
and use docking and functional analysis to propose
an alternative structure that is consistent with pre-
vious literature on PKC regulation. Mutagenesis
of predicted contact residues establishes that the
Ca2+-sensing C2 domain interacts intramolecularly
with the kinase domain and the carboxyl-terminal
tail, locking PKC in an inactive conformation.
Ca2+-dependent bridging of the C2 domain to mem-
branes provides the first step in activating PKC via
conformational selection. Although the placement
of the C1 domains remains to be determined, eluci-
dation of the structural basis for autoinhibition of
PKCbII unveils a unique direction for therapeutically
targeting PKC.
INTRODUCTION
Protein kinase C (PKC) isozymes transduce a myriad of signals
that result in phospholipid hydrolysis. As such, they play key
roles in a multitude of cellular processes, including controlling
the balance between cell survival and death, and their dysregu-
lation has been implicated in numerous diseases. Mounting evi-
dence suggests that PKC activity suppresses survival signaling
(Reyland, 2007); thus, it functions as a tumor suppressor, and
cancer-associated PKC mutations are generally loss of function
(Antal et al., 2015). In marked contrast, its activity is elevated in
neurodegenerative diseases such as spinocerebellar ataxia 14
(Ji et al., 2014; Verbeek et al., 2005) and ischemic neurodegen-
eration (Sieber et al., 1998) and in heart disease (Belin et al.,
2007; Bowling et al., 1999; Takeishi et al., 2000). From a thera-
peutic standpoint, identifying intramolecular interactions be-
tween the different PKC domains is essential for designing small
molecules or peptides that can either disrupt these contacts to1252 Cell Reports 12, 1252–1260, August 25, 2015 ª2015 The Authoopen up and activate PKC or clamp the domains closed to pre-
vent PKC activation.
The PKC family consists of nine genes that are grouped
according to their regulatory domains and, thus, the second
messengers that regulate them (Parker and Murray-Rust,
2004). Conventional PKC isozymes (a, b, and g) contain tandem
C1 domains, C1A and C1B, that bind diacylglycerol (DAG) and a
C2 domain that binds anionic phospholipids in a Ca2+-depen-
dent manner (Figure 1A); the C2 domain also contains phospha-
tidylinositol-4,5-bisphosphate (PIP2)-binding determinants that
direct conventional PKC isozymes to the plasma membrane.
Novel PKC (d, ε, h, and q) isozymes lack a functional C2 domain
and, therefore, are activated solely by DAG binding to the C1
domain, whereas atypical PKC (i and z) isozymes bind neither
of these second messengers. Conventional and novel PKC iso-
zymes are constitutively phosphorylated at three priming sites
(activation loop, turn motif, and hydrophobic motif), that trigger
a series of conformational changes that allow PKC to adopt an
autoinhibited conformation that is catalytically competent but
unable to signal in the absence of agonists (Antal et al., 2015;
Feng et al., 2000; Stensman et al., 2004). Specifically, the C1 do-
mains becomemasked to prevent basal recognition of DAG, and
the pseudosubstrate binds the substrate-binding cavity to
prevent substrate phosphorylation. Signals that result in phos-
pholipid hydrolysis activate conventional PKC isozymes by a
two-step mechanism: generation of Ca2+ recruits PKC to the
plasma membrane, where it binds its membrane-embedded
ligand, DAG. This latter event releases the pseudosubstrate,
thus activating PKC.
Elucidation of the structure of PKC has been challenging,
given that it is a highly dynamic, multi-module protein that
undergoes large conformational changes. The structures of the
isolated C1, C2, and kinase domains of conventional PKC iso-
zymes have been previously solved (Grodsky et al., 2006; Guer-
rero-Valero et al., 2009; Hommel et al., 1994). Themost complete
PKC crystal structure to date is that of PKCbII, in which electron
density is clearly evident for the C1B, C2, and kinase domains
and the carboxyl-terminal (C-term) tail (Leonard et al., 2011).
However, because the structure lacks adequate electron density
for the pseudosubstrate, the C1A domain, or any of the regions
connecting the domains to one another, the assignment of which
domains belong to a particular polypeptide, as opposed to other
symmetry mates, was challenging. The crystal lattice revealed
two possible contacts between the C2 and catalytic domains:
mode i involving intermolecular contacts with a distal surfacers
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Kinase Domain and C-Terminal Tail
(A) Schematic of the primary structure of PKCbII showing
domain composition, priming phosphorylation sites (activation
loop in pink; turn motif in orange; and hydrophobic motif in
green), and the proteolytically labile hinge that separates the
regulatory and catalytic moieties.
(B) Crystal structure of PKCbII showing the original interpreta-
tion of the location of the C2 domain that traces polypeptide
from the C1B to the C2 (mode i) and the alternative interpre-
tation in which the C2 domain binds the kinase domain by an
intramolecular interaction (mode ii). Both modes are present in
the crystal packing.
(C) C2 domain (yellow) docked onto a complex of the PKCbII
kinase domain (cyan) and the modeled pseudosubstrate (red).
(D) Complex of the PKCbII kinase domain (cyan) and themode ii
C2 domain (yellow) from the crystal packing with the modeled
pseudosubstrate (red), superimposed with the docked C2
domain (brown).
(E) Structure of the kinase domain:C2 domain:pseudosubstrate
complex showing the opening between the kinase domain
(cyan) and the C2 domain (yellow), through which the pseu-
dosubstrate:C1A linker (red) can be accommodated.
See also Figure S2.of the kinase domain C-term lobe and mode ii involving intramo-
lecular contacts with the catalytic cleft of the kinase (Figure 1B).
Leonard et al. (2011) hypothesized that binding of the pseudo-
substrate in the catalytic site of the kinase would cause a steric
clash with the C2 domain and, therefore, dismissed mode ii
as being functionally irrelevant. However, this latter pose is
supported by extensive literature establishing intramolecular
contacts between the C2 domain and C-term tail of conventional
PKC isozymes (Banci et al., 2002; Conrad et al., 1994; Corbala´n-
Garcı´a et al., 2003; Edwards and Newton, 1997a, 1997b; Feng
et al., 2000; Kheifets and Mochly-Rosen, 2007). This raises the
question as to whether the mode ii intradomain contacts might
represent the biologically relevant structure.
Here, we use structure/function analysis to test whether the
C2 domain clamps over the kinase domain to provide a previ-
ously undescribed mechanism of autoinhibition, in which not
only is the pseudosubstrate found in the substrate-binding
cavity, but the C2 domain also clamps this autoinhibited confor-
mation. From the crystal packing, we identify key ion pairs be-
tween the C2 domain and kinase domain or C-term tail and
show that reversal of one charge unfolds PKC and that reversal
of both charges re-clamps PKC in a closed conformation. Using
this information with subsequent structural modeling, we pro-
pose a model for the two-step activation of PKC. In this model,
(1) Ca2+ binding to the C2 domain pushes the equilibrium toward
the open conformation (C2 removed from kinase domain)
because theC2 domain is now retained at the plasmamembrane
via Ca2+ bridging to anionic phospholipids, and (2) binding of
DAG to the C1B domain repositions the pseudosubstrate-C1A
moiety to relieve autoinhibition. Our findings suggest that PKC
is activated via conformational selection of the open state of
the enzyme. Additionally, they open new avenues for therapeuti-
cally targeting PKC with small molecules or peptides that couldCelldisrupt or strengthen intramolecular contacts in order to modu-
late PKC activity.
RESULTS
PKCbII Crystal Structure Packing Reveals that the C2
Domain Interfaces with the Kinase Domain
Given the differences between the PKCbII structure and model
of activation (Leonard et al., 2011) with previous biochemical
analyses of PKC, we examined the reported crystal packing
to determine whether any other conformations could support
the known biology of PKC. Docking of the C2 domain onto a
complex of the kinase domain with a modeled pseudosubstrate
(Figure 1C) showed that the C2 domain can be bound to the
kinase domain with the pseudosubstrate present in its active
site in a way that is very similar to mode ii, with the RMSD being
13 A˚ (1,095 atoms) (Figure 1D). In this model, an opening be-
tween the catalytic and C2 domains would readily accommo-
date the presence of the linker between the pseudosubstrate
and C1A domain (Figures 1E). If this interaction were bio-
logically relevant, it would unveil yet another mechanism of
autoinhibition, with the C2 domain clamping over the kinase
domain to maintain the pseudosubstrate in the substrate-bind-
ing cavity.
Mutational Analysis Corroborates a C2:Kinase Domain
Interface
To test whether the C2 domain of PKCbII interfaces with the
kinase domain and the C-term tail in the closed, autoinhibited
conformation, we determined which residues are involved in
this interaction. Based on the crystal packing, Asp382 within
the kinase domain and Lys209 within the C2 domain were pre-
dicted to form hydrogen bonds (Figure 2A). To test this potentialReports 12, 1252–1260, August 25, 2015 ª2015 The Authors 1253
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Figure 2. Mutational Analysis Corroborates
a C2:Kinase Domain Interface
(A) Crystal structure of PKCbII showing predicted
ion pairs between the kinase domain (cyan) or the
C-terminal tail (gray) and the C2 domain (yellow).
(B–D) Normalized FRET ratio changes (mean ±
SEM) representing PDBu (200 nM)-induced PKC
translocation in COS7 cells co-expressing YFP-
tagged PKCbII wild-type (WT) or mutants and
plasma-membrane-targeted CFP.
(E) FRET ratio changes (mean ± SEM) representing
thapsigargin (Thaps; 5 mM)-induced followed by
PDBu (200 nM)-induced PKC translocation in
COS7 cells co-expressing YFP-tagged PKCbII
WT or mutant and plasma-membrane-targeted
CFP. r.u., relative units.
See also Figure S1.interaction, we mutated the negatively charged Asp382 to a
positively charged Lys and assessed whether this induced an
open conformation of the enzyme by displacing regulatory moi-
eties from the kinase domain. Note that we refer to an open
conformation of PKC as one in which the C1 and/or C2 domains
of PKC are displaced from the kinase domain and the pseudo-
substrate is out of the substrate-binding site, and we refer to a
closed conformation as one in which PKC is autoinhibited
through intramolecular interactions with its pseudosubstrate
and regulatory domains.We have previously shown that unphos-
phorylated PKCbII adopts an open conformation that, because1254 Cell Reports 12, 1252–1260, August 25, 2015 ª2015 The Authorsof unmasked C1A and C1B domains,
translocates more rapidly to the plasma
membrane upon treatment with the C1
domain ligand, phorbol 12,13-dibutyrate
(PDBu), compared with matured (phos-
phorylated) PKC that has undergone
conformational transitions to mask its C1
domains (Antal et al., 2014). Indeed,
when the Asp382-Lys209 interaction was
disrupted by a D382K mutation, the pro-
tein translocated more rapidly (Figure 2B;
half-time [t1/2] = 1.7 min ± 0.1 min versus
3.5 min ± 0.2 min), indicating that it was
in a more open conformation with its
C1 domains exposed. Simultaneously
inverting the charges of both Asp382
and Lys209 (D382K/K209D) rescued the
translocation kinetics (t1/2 = 3.4 min ±
0.2 min), corroborating the interpretation
that these residues interact with each
other. Glu655 and Lys205 are also posi-
tioned in proximity so that they could
interact electrostatically (Figure 2A).
Similar to the Asp382-Lys209 pair,
mutating Glu655 to a Lys also increased
the translocation rate (t1/2 = 1.6 min ±
0.1 min) induced by PDBu, and simulta-
neously reversing the charges of both
Glu655 and Lys205 rescued the translo-cation kinetics (Figure 2C; t1/2 = 2.9 min ± 0.2 min). Lys209 is
part of the C2 domain lysine-rich cluster that binds PIP2 (Corba-
la´n-Garcı´a et al., 2003), and Lys205 interacts with the phospha-
tidylserine (PS) head groups (Verdaguer et al., 1999). Because
these mutations disrupted the plasma-membrane-sensing role
of the C2 domain (Scott et al., 2013), they augmented basal
and PDBu-dependent PKC association with the DAG (1,2-sn-di-
acylglycerol)-rich Golgi through the now-dominant C1 domain
binding (data not shown). Thus, we could not assess the plasma
membrane translocation kinetics of thesemutants. However, our
results are consistent with these C2 domainmutants adopting an
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(A) Charge reversal of the ion pair partner in the
C2 domain (K205E) would rescue the fast trans-
location kinetics of the E655K C-terminal tail
mutation in the case of an intermolecular (left), but
not intramolecular (right), C2:kinase interaction.
(B) Normalized FRET ratio changes (mean ± SEM)
representing PDBu (200 nM)-induced PKC
translocation in COS7 cells co-expressing plasma
membrane-targeted CFP and either YFP-PKCbII-
WT, YFP-PKCbII-E655K, or both YFP-PKCbII-
E655K and RFP-PKCbII-K205E. WT, wild-type.open conformation in which the C1 domain is able to bind basal
DAG at the Golgi. As mentioned earlier, the plasma membrane
translocation kinetics of either charge reversal double mutant
(K209D/D382K and K205E/E655K) was rescued, and so was
their localization (data not shown), because they were able to
adopt a closed conformation. As a negative control, mutating
the nearby Glu657 within the C-term tail to a Lys had no effect
on the translocation kinetics (Figure 2C; t1/2 = 4.0 min ±
0.2 min) because this residue does not interface with the C2
domain. Furthermore, mutating both residues involved in the
interaction with the C2 domain (D382K and E655K) resulted in
a more open conformation, as it further increased the rate of
translocation (Figure 2D; t1/2 = 1.1 min ± 0.1 min) induced by
PDBu. However, this conformation was not as open as that
of unprocessed, kinase-dead PKCbII (Antal et al., 2014), sug-
gesting that there are other contributing points of contact
within the regulatory domain. A quadruple mutant in which
charges in both ion pairs were reversed (i.e., K205E/E655K/
K209D/D382K) displayed only partial recovery (t1/2 = 1.7 min ±
0.1 min), likely because mutating all four residues significantly
reduced processing phosphorylations (data not shown). Note
that all other mutants were effectively processed by phosphory-
lation (Figure S1).
To ensure that the mutations that disrupted the C2:kinase
domain interface indeed disengaged the C2 domain to allow
it to favor Ca2+-dependent lipid binding, we monitored the
steady-state levels of binding of the PKCbII-D382K/E655K
mutant enzyme to the plasmamembrane upon elevation of intra-
cellular Ca2+ with thapsigargin, a sarco/ER Ca2+-ATPase inhibi-
tor (Rogers et al., 1995). Elevation of Ca2+ resulted in an 2-fold
increase in the steady-state binding of the PKCbII-D382K/E655K
to the plasma membrane (Figure 2E), consistent with disrup-
tion of these ion pairs favoring an open conformation with an
exposed C2 domain. Moreover, this mutant translocated to
membranes with much faster kinetics upon subsequent stimula-
tion with PDBu, corroborating the open conformation. Kinase-
dead PKCbII-D466N, which has fully exposed C1A and C1B
domains (Antal et al., 2014; Gould et al., 2011; Shi et al., 2010),
translocated rapidly and more completely to the membrane
upon elevation of Ca2+(Figure 2E), revealing that the C2 domain,
similar to the C1A and C1B domains, is highly exposed in un-
primed PKC. Thus, the C2 domain of the PKCbII-D382K/E655K
favors a more open conformation than that of wild-type but not
as open as that of the kinase-dead PKC, likely because of addi-
tional points of contact between the C2 and kinase domains.CellThe C2:Kinase Domain Interaction Is Intramolecular
To exclude the possibility that the C2:kinase domain interaction
is intermolecular, as opposed to intramolecular, we examined
whether an intermolecular interaction between a yellow fluores-
cent protein (YFP)-tagged PKCbII E655K mutant and a red
fluorescent protein (RFP)-tagged PKCbII K205E mutant could
rescue the fast translocation kinetics of the E655K mutant
(Figure 3A). In contrast to the rescue induced by introducing a
complementary C2 domain mutation into the same polypeptide
as the kinase domain mutation (see Figure 2C; t1/2 = 1.0 min ±
0.1 min versus 2.9 min ± 0.2 min), the presence of a C2 domain
mutation on another PKCbII molecule did not rescue the fast
translocation kinetics for the C-term tail mutant (Figure 3B).
These data are consistent with an intramolecular, and not inter-
molecular, C2:kinase domain interaction and support biophysi-
cal studies showing that cellular PKCbII translocates to plasma
membranes as a monomer (L. Kaestner and P. Lipp, personal
communication) and biochemical studies showing that pure
PKC is fully active as a monomer (Hannun and Bell, 1986).
PKC Activation Is Insensitive to Phe629
Next, we investigated the physiological significance of the previ-
ously suggested allosteric activation model, which postulates
that Phe629 of the NFD helix (residues 628–630) controls the ac-
tivity of PKC (Leonard et al., 2011). Specifically, the C1B was
proposed to clamp the NFD in a low-activity conformation in
which the Phe is displaced from the active site, with binding of
the C1B domain to membranes releasing the Phe to interact
with the adenine ring of ATP. However, mutation of Phe629 to
Ala resulted in a kinase whose cellular activation kinetics and
magnitude were indistinguishable from that of the wild-type
enzyme, in response to both natural agonists and phorbol esters
(Figure 4C). This suggests that Phe629 is not a key regulator of
the physiological activation of PKC.
DISCUSSION
We propose an alternate structure for PKCbII, based on re-anal-
ysis of the crystal packing of PKCbII (Leonard et al., 2011), that
reveals how the C2 domain provides an additional layer of
autoinhibition to ensure minimal signaling in the absence of acti-
vators. This structure (mode ii in Figure 1B), in which the C2
domain clamps over the kinase domain, is validated by muta-
genesis of interacting surfaces. Specifically, disruption of ion
pairs at the C2:kinase domain/C-term tail interface unclampsReports 12, 1252–1260, August 25, 2015 ª2015 The Authors 1255
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Figure 4. Mutation of Phe629 Does Not Affect PKC Activation
Normalized FRET ratio changes (mean ± SEM) showing agonist-dependent
PKC activity of the indicated RFP-tagged PKCbII constructs or RFP control
(endogenous) in COS7 cells co-expressing CKAR. WT, wild-type; r.u., relative
units.the C2 domain, and reversal of charges in this ion pair maintains
the clamped conformation. Additionally, we show that disruption
of an ion pair is not rescued by introducing the opposite charge
into a separate PKCmolecule, establishing that monomeric PKC
binds its own C2 domain. These data support a model in which
the C2 domain forms an intramolecular clamp with the kinase
domain and C-term tail. Taken together with the extensive
biochemical analyses on PKCbII regulation, we propose amodel
(Figure 5) for the activation mechanism of PKC that reveals
how conformational regulation results in minimal signaling in
the absence of activators, thus optimizing the signaling output
of the enzyme.
Our structure and model are supported by prior biochemical
studies indicating that the C2 domain of PKCbII interfaces with
the C-term tail to maintain PKC in a closed, inactive conforma-
tion. Specifically, the C-term tail of PKCbII has been previously
suggested to interface with the C2 domain because the C2-
domain-mediated Ca2+ affinity is sensitive to the composition
of the C-term tail (Edwards and Newton, 1997b) and to the phos-
phorylation state of the hydrophobic motif within the C-term tail
(Edwards and Newton, 1997a); additionally, constructs with an
Ala at this phosphorylation site adopt an open conformation
that associates with the plasma membrane, unless Ca2+ is
chelated (Feng et al., 2000). Yet another study established that
PKC is in a closed conformation in which neither PIP2 nor DAG
can bind in the absence of Ca2+ (Corbala´n-Garcı´a et al., 2003).
Further evidence for intramolecular autoinhibitory contacts
comes from studies by Mochly-Rosen and colleagues that re-
vealed that the RACK (Receptor for Activated C-kinase )-binding
site within the C-term tail of PKCbII interacts with a sequence in
the C2 domain that mimics the PKC binding site on RACK1256 Cell Reports 12, 1252–1260, August 25, 2015 ª2015 The Autho(pseudo-RACK), maintaining PKC in an inactive conformation
(Banci et al., 2002). These findings are consistent with the C2
domain of PKCbII interacting with the C-term tail to maintain
the enzyme unresponsive to basal levels of agonists.
The C2 domain of the related PKCa has also been reported to
contribute to its autoinhibition (Parissenti et al., 1998; Riedel
et al., 1993). For example, the deletion of 20 amino acids within
its C2 domain induced constitutive activity of PKCa (Rotenberg
et al., 1998). This autoinhibitory interaction was mediated by
negatively charged residues in the C-term tail and a lysine-rich
cluster in the C2 domain (Stensman and Larsson, 2007). Consis-
tent with our work on PKCbII, reversing the charge of either of
these interacting residues resulted in a higher sensitivity to
DAG and, thus, enhanced membrane translocation, whereas
simultaneously reversing both charges rescued the enhanced
translocation phenotype (Stensman and Larsson, 2007). Taken
together, these findings suggest that the C2 domain of PKCa
has a similar placement to that of PKCbII, with conservation of
charge at critical residues within the interfacing surfaces.
Of the two observed modes in the crystal lattice (Leonard
et al., 2011), several arguments were presented against the intra-
molecularly clamped mode ii that our biochemical data support.
First, Hurley and coworkers hypothesized that the pseudo-
substrate would be excluded from the substrate-binding cavity
in this conformation. However, molecular modeling of the pseu-
dosubstrate in the substrate-binding cavity reveals that there is
minimal steric hindrance, especially given the highly flexible
nature of the Ca2+-binding loops (Figure 1C). Indeed, a clear
opening is present and would accommodate threading of the
segment following the pseudosubstrate to allow it to connect
to the C1A domain that begins ten residues past the pseudosub-
strate (Figures 1E). Thus, the pseudosubstrate could occupy the
active site in mode ii without significant structural changes.
Although protein-protein docking is not a flawless method, given
that it cannot directly address flexibility of protein main chains,
our mutagenesis data confirm this mode ii conformation. Sec-
ond, Leonard et al. (2011) reasoned that Ca2+ would not bind
the C2 domain in mode ii. However, the affinity of the C2 domain
for Ca2+ is over three orders ofmagnitude lower in the absence of
anionic lipids (Nalefski and Newton, 2001), because anionic
lipids are required to stabilize Ca2+ binding (Nalefski and Falke,
1996). Stopped flow kinetic experiments suggest that PKC col-
lides with membranes at the diffusion-controlled limit but rapidly
dissociates because of unfavorable electrostatic interactions.
Elevation of intracellular Ca2+ allows anionic lipids to retain
PKC on membranes, increasing the lifetime of the membrane-
bound complex by several orders of magnitude. This induces a
conformational change that results in an increase two orders of
magnitude higher in proteolytic sensitivity of the hinge connect-
ing the C2 domain and kinase domain (Keranen and Newton,
1997; Kishimoto et al., 1983; Young et al., 1988). In fact, no
cleavagewas observed between the C1B andC2 domains under
any condition tested (Keranen and Newton, 1997), as the model
proposed by Leonard et al. (2011) suggests, based on the pres-
ence of a large flexible linker between these domains. Rather,
Ca2+-dependent binding to membranes results in unmasking
of the hinge separating the C2 domain from the kinase domain
(Keranen and Newton, 1997), with subsequent activationrs
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Figure 5. Model of PKCbII Activation
(A) Unprimed PKCbII is in amembrane-associated,
open conformation in which its C1A, C1B, and C2
domains are fully exposed and the pseudosub-
strate and C-terminal tail are unmasked.
(B) Upon priming phosphorylation at its activation
loop (T500, magenta) by PDK-1, followed by au-
tophosphorylation at the turn motif (T641, orange)
and the hydrophobic motif (S660, green), PKCbII
matures into a closed conformation in which the
C2 domain interfaces with the kinase domain
and traps the pseudosubstrate into the substrate-
binding site, both C1 domains become masked,
and the primed enzyme localizes to the cytosol.
(C) In response to agonists that promote PIP2
hydrolysis, Ca2+ binds cytosolic PKCbII via a low-
affinity interaction so that upon the next diffusion-
controlled membrane encounter, the Ca2+-bound
C2 domain is retained at the plasma membrane via
Ca2+-bridging to anionic lipids and binding to PIP2.
(D) Pre-targeted PKC binds the membrane-
embedded ligand, DAG, predominantly via the
C1B domain, resulting in release of the pseudo-
substrate from the substrate-binding cavity,
thereby activating PKC. Only one of the C1 do-
mains binds DAG in the membrane at a time.resulting in the exposure of the pseudosubstrate segment (Orr
et al., 1992). This supports a model in which Ca2+ provides
conformational selection by favoring an equilibrium in which
the C2 domain is pulled away from the kinase domain via
bridging to the membrane.
SAXS data revealed an elongated shape of PKCbII, which Leo-
nard et al. (2011) considered at odds with the intramolecularly
clampedmode ii. The program AutoGNOMwas used by Leonard
et al. (2011) to determine that the maximum linear dimension
(Dmax) of the complex was 100 A˚. Ourmodel of the kinase domain
and C2 domain in mode ii is 83 A˚ (Figure 1E) but excludes the
C1A and C1B domains, which would increase the Dmax, because
their exact placement within the full-length structure is yet to be
determined. Additional experiments such as sedimentation
studiesor electronmicroscopywouldbe required for the indepen-
dent estimate of Dmax (Moore, 1980). Another limitation of SAXS
analysis is that it considers proteins as rigid bodies; however,
our model suggests that the C2 domain is highly dynamic and al-
ternates between variousconformations until Ca2+-bindingdrives
the equilibrium toward the membrane-bound, open conforma-
tion. It is known that interdomain dynamics can significantly alter
SAXS profiles and lead to misinterpretation of SAXS data (Ber-
nado´, 2010). Therefore, the existing SAXS data (Leonard et al.,
2011) cannot aid in distinguishing between the two models in
question. A complete crystal structure in which all domains are
present and with high enough resolution to resolve the linker re-
gions, corroborated biochemically by mutagenesis, would be
necessary todetermine theexact conformationof theC1domains
in the inactive conformationof PKCbII. However, ourmutagenesis
data clearly support our model of the C2 domain interfacing with
the kinase domain and C-term tail.
Our data suggest that the NFD helix does not serve as the
linchpin for activation of PKC, as proposed by Hurley and col-
leagues, who suggested that binding of the NFD helix to theCellC1B domain positions Phe629 away from the ATP binding site
to reduce catalysis. However, a Phe-to-Ala mutation results in
a PKC whose activity in cells is indistinguishable from that of
wild-type enzyme. Mutation of the corresponding residue in
PKA (Phe327) to Ala resulted in only a modest decrease in cata-
lytic rate constant, kcat (from 26 s
1 to 20 s1), and although the
Michaelis-Menten constant, KM, for ATP was increased approx-
imately 10-fold (from 20 mM to 249 mM) (Yang et al., 2009), this is
20-fold lower than the intracellular concentration of ATP, sug-
gesting limited biological relevance. Based on this mechanism,
Leonard et al. (2011) proposed an intermediate step in the acti-
vation of PKC in which the pseudosubstrate is released from
the active site but the enzyme is inactive because the C1B is still
bound to the kinase domain, positioning Phe629 away from the
ATP binding site. However, release of the pseudosubstrate cor-
relates with the activation of PKC under all conditions examined
(Orr et al., 1992; Orr and Newton, 1994). Thus, the NFD helix of
PKCbII is not a key regulator of kinase activity; rather, release
of the pseudosubstrate is the key determinant for activation.
Figure 5 presents a model for the regulation of PKC that takes
into account the conformational sensing by the C2 domain. We
have previously shown that newly synthesized PKC (Figure 5A)
is in an open conformation (Antal et al., 2014). Upon maturation
by phosphorylation, conformational rearrangements mask
PKC’s C1 domains, thus reducing its apparent affinity for DAG,
so there is no binding to basal DAG. Now, we build on this model
of autoinhibition to show that the C2 domain clamps over the ki-
nase domain, tethering the pseudosubstrate in place (Figure 5B)
for even more effective autoinhibition than previously proposed.
This explains why the activation loop is inaccessible to PDK-1 or
to phosphatases in the autoinhibited conformation (Dutil and
Newton, 2000). Upon elevation of intracellular Ca2+, conforma-
tional selection allows the Ca2+-bound C2 domain to engage
on the membrane, inducing a large hinge motion that rendersReports 12, 1252–1260, August 25, 2015 ª2015 The Authors 1257
the C2:kinase domain linker 100-fold more sensitive to limited
proteolysis (Figure 5C) (Keranen and Newton, 1997). This mem-
brane-bound species is now able to bind DAG, via the C1B
domain, an event that pulls the pseudosubstrate out of the sub-
strate-binding cavity to allow full activation of PKC (Figure 5D).
Note that only one C1 domain binds ligand at a time, as deter-
mined by seminal studies by Nishizuka and Blumberg, establish-
ing that the stoichiometry of ligand binding of full-length PKC is
1 mol DAG or 1 mol phorbol ester per mole of PKC (Kikkawa
et al., 1983; Ko¨nig et al., 1985), a finding that has been confirmed
many times (Giorgione et al., 2003; Hannun et al., 1985; Quest
and Bell, 1994; Solodukhin et al., 2007).
Two striking features of the PKC structure are now apparent.
First, the C2 domain provides an additional layer of autoinhibi-
tion to ensure no basal signaling of PKC in the absence of ago-
nists. Thus, activation requires the release of the C2 domain from
the kinase domain, followed by the release of the pseudosub-
strate from the substrate-binding cavity. Second, intramolecular
interactions can now be targeted in therapies. For example, in
cancer therapies, where PKC activity should be enhanced (Antal
et al., 2015), small molecules or peptides that destabilize the
clamped conformation of PKCbII will allow it to be more respon-
sive to second messengers. Conversely, in therapies for neuro-
degenerative or heart diseases where PKC activity should be
reduced, small molecules or peptides can be designed to stabi-
lize the clamped conformation. Because the C-term tails of the
PKC isozymes are highly variable, this method could provide a
unique isozyme-specific method of regulating the activity of indi-
vidual isozymes.
EXPERIMENTAL PROCEDURES
Plasmid Constructs, Antibodies, and Reagents
C-terminally tagged rat PKCbII-YFP (Dries et al., 2007) and the membrane-
targeted CFP (Violin et al., 2003) have been previously described. Rat PKCbII
was RFP-tagged at the C terminus. All mutants were generated by Quik-
Change site-directed mutagenesis (Stratagene). The pan-anti-phospho-PKC
activation loop antibody was previously described (Dutil et al., 1998), and
the anti-PKCb (610128) antibody was from BD Transduction Laboratories.
PDBu and thapsigargin were purchased from Calbiochem. All other materials
were reagent grade.
Cell Culture, Transfection, and Immunoblotting
COS7 cells were cultured in DMEM (Cellgro) containing 10% fetal bovine
serum (Atlanta Biologicals) and 1% penicillin/streptomycin (GIBCO) at 37C
in 5% CO2. Transient transfection was carried out using jetPRIME (PolyPlus
Transfection) or FuGENE 6 transfection reagents (Roche Applied Science)
for 24 hr. Cells were lysed in 50 mM Tris (pH 7.4), 1% Triton X-100, 50 mM
NaF, 10 mM Na4P2O7, 100 mM NaCl, 5 mM EDTA, 1 mM Na3VO4, 1 mM
PMSF, 40 mg/ml leupeptin, and 1 mM microcystin. Whole cell lysates were
analyzed by SDS-PAGE and western blotting via chemiluminescence on a
FluorChem Q imaging system (ProteinSimple).
FRET Imaging and Analysis
Cells were imaged as described previously (Gallegos et al., 2006). COS7 cells
were co-transfected with the indicated YFP-tagged PKC construct and
plasma membrane targeted. Baseline images were acquired every 7 or 15 s
for R2 min before ligand addition. Fluorescence resonance energy transfer
(FRET) ratios represent mean ± SEM from at least three independent
experiments. All data were normalized to the baseline FRET ratio of each indi-
vidual cell. When comparing translocation kinetics, data were also normalized
to the maximal amplitude of translocation for each, as previously described1258 Cell Reports 12, 1252–1260, August 25, 2015 ª2015 The Autho(Antal et al., 2015). This normalization was performed because the maximal
amplitude of translocation of the mutants varied, possibly because of changes
in the orientation or distance of the fluorophores caused by differential folding
of the mutant kinases. Statistical significance was determined via Student’s
t test performed in GraphPad Prism 6.0a (GraphPad Software). The half-time
of translocation was calculated by fitting the data to a non-linear regression
using a one-phase exponential association equation with Graph Pad Prism
6.0a (GraphPad Software).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and two figures and can be found with this article online at http://dx.doi.org/
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